Eribulin Mesylate (Halaven) — CPB 0831 | AETNA Coverage Update

Aetna modified CPB 0831 for eribulin mesylate (Halaven), effective September 26, 2025. Here's what billing teams need to know.

Aetna, a CVS Health company, updated its eribulin mesylate coverage policy under CPB 0831 Aetna system, covering the chemotherapy agent Halaven (HCPCS J9179) for breast cancer and soft tissue sarcoma. The policy defines exact approval criteria, continuation of therapy requirements, and a long list of non-covered indications that will generate claim denials if your team isn't paying attention. If you bill J9179 for any Aetna member, audit your documentation before September 26, 2025.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Eribulin Mesylate (Halaven) — CPB 0831
Policy Code	CPB 0831
Change Type	Modified
Effective Date	September 26, 2025
Impact Level	High
Specialties Affected	Medical Oncology, Hematology/Oncology, Infusion Centers
Key Action	Confirm HER2 status documentation and sarcoma subtype in the medical record before billing J9179 for any Aetna member

---

Aetna Eribulin Mesylate Coverage Criteria and Medical Necessity Requirements 2025

The real issue with the Aetna eribulin mesylate coverage policy is how tightly it ties medical necessity to specific tumor characteristics. This isn't a blanket "metastatic breast cancer" approval — the criteria branch based on HER2 status, and sarcoma approvals depend on exact anatomical subtype. A missing detail in the documentation equals a denial.

Breast Cancer

Aetna covers eribulin mesylate (Halaven) for recurrent or metastatic breast cancer, or breast cancer with no response to preoperative systemic therapy. Coverage splits into two paths based on HER2 status.

For HER2-negative disease, eribulin must be used as a single agent. That's it. No combination regimens qualify on the HER2-negative side. Your documentation needs to confirm HER2-negative status — not just a diagnosis of metastatic breast cancer.

For HER2-positive disease, eribulin must be used in combination with either margetuximab-cmkb (J9353) or trastuzumab (J9355). Solo eribulin for HER2-positive disease doesn't meet criteria. If the oncologist is using a different combination partner, don't expect approval.

Soft Tissue Sarcoma

Aetna covers eribulin as single-agent therapy for four specific soft tissue sarcoma subtypes:

"Soft tissue sarcoma" as a general diagnosis code isn't enough. The medical record and prior authorization request need to identify the specific subtype. Uterine leiomyosarcoma is explicitly excluded — Aetna calls it experimental. That's a meaningful carve-out given how often leiomyosarcoma appears in oncology billing.

Continuation of Therapy

Aetna covers continuation of eribulin therapy when the member has an approved indication from the list above and shows no evidence of unacceptable toxicity or disease progression. This means ongoing reauthorization requests need clinical documentation confirming treatment response and tolerability. Build that into your reauthorization workflow now — don't wait until the prior authorization expires.

Dosing Thresholds That Affect Reimbursement

Dosing details matter for J9179 billing because eribulin mesylate is billed per 0.1 mg. The standard dose is 1.4 mg/m² IV over two to five minutes on days one and eight of a 21-day cycle. Dose reductions apply for hepatic and renal impairment:

#	Covered Indication Copy
1	Mild hepatic impairment (Child-Pugh A): 1.1 mg/m²
2	Moderate hepatic impairment (Child-Pugh B): 0.7 mg/m²
3	Moderate or severe renal impairment (CrCl 15–49 mL/min): 1.1 mg/m²

If the billed units on J9179 don't match the dose in the medical record, you're exposed to a claim denial on medical necessity grounds. This is a common audit flag for chemotherapy billing. Make sure your charge capture reflects the actual administered dose, especially for patients with hepatic or renal impairment on reduced doses.

---

Aetna Eribulin Mesylate Exclusions and Non-Covered Indications

Aetna's exclusion list for eribulin is long and specific. The payer classifies all of the following as experimental, investigational, or unproven for eribulin mesylate. Billing J9179 for any of these indications will result in a claim denial:

That last one deserves emphasis. Uterine leiomyosarcoma is a sarcoma — and some billing teams assume sarcoma coverage is broad. It isn't here. Aetna draws a hard line between covered sarcoma subtypes and uterine leiomyosarcoma. If your oncology group treats this diagnosis, flag it now.

The brain metastases exclusion also has nuance. A breast cancer patient with brain metastases can still qualify — but only if they independently meet the breast cancer criteria in Section I. If they don't, the brain metastases indication is excluded. Your prior auth team needs to understand that distinction before submitting.

---

Coverage Indications at a Glance

---

Aetna Eribulin Mesylate Billing Guidelines and Action Items 2025

These are the specific steps your billing team needs to take before the effective date of September 26, 2025.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Eribulin Mesylate Under CPB 0831

Covered HCPCS Code (When Selection Criteria Are Met)

Code	Type	Description Copy
J9179	HCPCS	Injection, eribulin mesylate, 0.1 mg

Related CPT Code

Code	Type	Description Copy
96409	CPT	Chemotherapy administration; intravenous, push technique, single or initial substance/drug

Key ICD-10-CM Diagnosis Codes

A note on ICD-10 coding for eribulin billing: the covered ICD-10 codes overlap with a broad range of malignancies. Payer systems don't auto-approve based on diagnosis code alone — the specific indication, HER2 status, and sarcoma subtype documented in the prior auth are what drive coverage decisions. A valid ICD-10 code does not substitute for proper clinical documentation.

---